Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 37.31
(-0.8%)
USD 37.31
(-0.8%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.4 Billion USD | 4.12% |
| 2022 | 1.34 Billion USD | 15.85% |
| 2021 | 1.16 Billion USD | 55.01% |
| 2020 | 749 Million USD | 5.49% |
| 2019 | 710 Million USD | 24.95% |
| 2018 | 568.21 Million USD | 6.58% |
| 2017 | 533.11 Million USD | 6.49% |
| 2016 | 500.63 Million USD | 25.92% |
| 2015 | 397.57 Million USD | 5.88% |
| 2014 | 375.5 Million USD | 149.78% |
| 2013 | 150.33 Million USD | 4.41% |
| 2012 | 143.99 Million USD | -33.17% |
| 2011 | 215.45 Million USD | 44.83% |
| 2010 | 148.76 Million USD | 1196.06% |
| 2009 | 11.47 Million USD | -93.34% |
| 2008 | 172.43 Million USD | 5.88% |
| 2007 | 162.86 Million USD | 22.62% |
| 2006 | 132.82 Million USD | -5.07% |
| 2005 | 139.91 Million USD | -40.87% |
| 2004 | 236.61 Million USD | 10.88% |
| 2003 | 213.39 Million USD | 2.96% |
| 2002 | 207.25 Million USD | 64.87% |
| 2001 | 125.71 Million USD | 22.94% |
| 2000 | 102.25 Million USD | 17.13% |
| 1999 | 87.3 Million USD | 12.36% |
| 1998 | 77.7 Million USD | 37.52% |
| 1997 | 56.5 Million USD | 183.92% |
| 1996 | 19.9 Million USD | 323.4% |
| 1995 | 4.7 Million USD | -49.46% |
| 1994 | 9.3 Million USD | 5.68% |
| 1993 | 8.8 Million USD | 31.34% |
| 1992 | 6.7 Million USD | 34.0% |
| 1991 | 5 Million USD | 455.56% |
| 1990 | 900 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.76 Billion USD | 0.58% |
| 2024 Q1 | 1.75 Billion USD | 0.73% |
| 2023 Q2 | 1.47 Billion USD | 8.3% |
| 2023 FY | 1.4 Billion USD | 4.12% |
| 2023 Q3 | 1.4 Billion USD | -4.75% |
| 2023 Q4 | 1.4 Billion USD | -0.26% |
| 2023 Q1 | 1.36 Billion USD | 1.19% |
| 2022 Q2 | 1.22 Billion USD | 0.09% |
| 2022 FY | 1.34 Billion USD | 15.85% |
| 2022 Q1 | 1.22 Billion USD | 5.27% |
| 2022 Q4 | 1.34 Billion USD | 9.85% |
| 2022 Q3 | 1.22 Billion USD | 0.09% |
| 2021 FY | 1.16 Billion USD | 55.01% |
| 2021 Q1 | 847.97 Million USD | 13.21% |
| 2021 Q4 | 1.16 Billion USD | -4.84% |
| 2021 Q2 | 1.21 Billion USD | 43.71% |
| 2021 Q3 | 1.22 Billion USD | 0.12% |
| 2020 Q4 | 749 Million USD | -6.25% |
| 2020 Q1 | 779.59 Million USD | 9.8% |
| 2020 FY | 749 Million USD | 5.49% |
| 2020 Q2 | 789.18 Million USD | 1.23% |
| 2020 Q3 | 798.93 Million USD | 1.24% |
| 2019 Q2 | 587 Million USD | -7.89% |
| 2019 Q3 | 656.25 Million USD | 11.8% |
| 2019 Q4 | 710 Million USD | 8.19% |
| 2019 FY | 710 Million USD | 24.95% |
| 2019 Q1 | 637.27 Million USD | 12.15% |
| 2018 Q3 | 619 Million USD | 1.45% |
| 2018 Q4 | 568.21 Million USD | -8.21% |
| 2018 FY | 568.21 Million USD | 6.58% |
| 2018 Q1 | 541.63 Million USD | 1.6% |
| 2018 Q2 | 610.13 Million USD | 12.65% |
| 2017 Q2 | 516.53 Million USD | -11.07% |
| 2017 Q3 | 584.49 Million USD | 13.16% |
| 2017 Q4 | 533.11 Million USD | -8.79% |
| 2017 FY | 533.11 Million USD | 6.49% |
| 2017 Q1 | 580.8 Million USD | 16.01% |
| 2016 Q4 | 500.63 Million USD | 4.23% |
| 2016 FY | 500.63 Million USD | 25.92% |
| 2016 Q1 | 395.45 Million USD | -0.53% |
| 2016 Q2 | 473.95 Million USD | 19.85% |
| 2016 Q3 | 480.33 Million USD | 1.34% |
| 2015 Q3 | 463.98 Million USD | 20.1% |
| 2015 Q4 | 397.57 Million USD | -14.31% |
| 2015 Q1 | 452.7 Million USD | 20.56% |
| 2015 FY | 397.57 Million USD | 5.88% |
| 2015 Q2 | 386.31 Million USD | -14.66% |
| 2014 Q3 | 227.05 Million USD | 0.82% |
| 2014 Q2 | 225.2 Million USD | 0.81% |
| 2014 Q1 | 223.4 Million USD | 48.6% |
| 2014 FY | 375.5 Million USD | 149.78% |
| 2014 Q4 | 375.5 Million USD | 65.38% |
| 2013 Q4 | 150.33 Million USD | -31.6% |
| 2013 Q2 | 218 Million USD | 0.81% |
| 2013 Q1 | 216.26 Million USD | 50.19% |
| 2013 FY | 150.33 Million USD | 4.41% |
| 2013 Q3 | 219.8 Million USD | 0.82% |
| 2012 Q1 | 217.35 Million USD | 0.89% |
| 2012 Q3 | 221.27 Million USD | -1.98% |
| 2012 Q4 | 143.99 Million USD | -34.93% |
| 2012 Q2 | 225.73 Million USD | 3.86% |
| 2012 FY | 143.99 Million USD | -33.17% |
| 2011 Q1 | 150.04 Million USD | 0.87% |
| 2011 FY | 215.45 Million USD | 44.83% |
| 2011 Q3 | 212.85 Million USD | 5.76% |
| 2011 Q2 | 201.26 Million USD | 34.13% |
| 2011 Q4 | 215.45 Million USD | 1.22% |
| 2010 Q3 | 145.33 Million USD | 0.46% |
| 2010 Q2 | 144.67 Million USD | 2.17% |
| 2010 Q1 | 141.6 Million USD | 1133.73% |
| 2010 FY | 148.76 Million USD | 1196.06% |
| 2010 Q4 | 148.76 Million USD | 2.36% |
| 2009 Q3 | 12.53 Million USD | -90.51% |
| 2009 Q1 | 131.08 Million USD | -23.98% |
| 2009 FY | 11.47 Million USD | -93.34% |
| 2009 Q2 | 132.1 Million USD | 0.78% |
| 2009 Q4 | 11.47 Million USD | -8.41% |
| 2008 Q3 | 167.97 Million USD | 0.04% |
| 2008 Q4 | 172.43 Million USD | 2.66% |
| 2008 FY | 172.43 Million USD | 5.88% |
| 2008 Q1 | 162.89 Million USD | 0.02% |
| 2008 Q2 | 167.91 Million USD | 3.08% |
| 2007 FY | 162.86 Million USD | 22.62% |
| 2007 Q1 | 168.38 Million USD | 26.78% |
| 2007 Q2 | 166.55 Million USD | -1.09% |
| 2007 Q3 | 164.72 Million USD | -1.1% |
| 2007 Q4 | 162.86 Million USD | -1.13% |
| 2006 FY | 132.82 Million USD | -5.07% |
| 2006 Q1 | 137.94 Million USD | -1.41% |
| 2006 Q2 | 136.17 Million USD | -1.28% |
| 2006 Q3 | 134.73 Million USD | -1.06% |
| 2006 Q4 | 132.82 Million USD | -1.42% |
| 2005 Q4 | 139.91 Million USD | -1.36% |
| 2005 Q3 | 141.84 Million USD | -41.97% |
| 2005 Q2 | 244.43 Million USD | 0.44% |
| 2005 Q1 | 243.35 Million USD | 2.85% |
| 2005 FY | 139.91 Million USD | -40.87% |
| 2004 Q4 | 236.61 Million USD | 3.16% |
| 2004 FY | 236.61 Million USD | 10.88% |
| 2004 Q3 | 229.36 Million USD | 2.38% |
| 2004 Q2 | 224.03 Million USD | 2.04% |
| 2004 Q1 | 219.55 Million USD | 2.89% |
| 2003 Q2 | 190.22 Million USD | -4.87% |
| 2003 Q3 | 189.39 Million USD | -0.44% |
| 2003 FY | 213.39 Million USD | 2.96% |
| 2003 Q1 | 199.95 Million USD | -3.52% |
| 2003 Q4 | 213.39 Million USD | 12.68% |
| 2002 Q2 | 191.66 Million USD | 43.11% |
| 2002 Q1 | 133.92 Million USD | 6.53% |
| 2002 FY | 207.25 Million USD | 64.87% |
| 2002 Q4 | 207.25 Million USD | 15.89% |
| 2002 Q3 | 178.84 Million USD | -6.69% |
| 2001 Q1 | 104.45 Million USD | 2.15% |
| 2001 Q4 | 125.71 Million USD | 1.67% |
| 2001 Q3 | 123.65 Million USD | 6.9% |
| 2001 Q2 | 115.66 Million USD | 10.73% |
| 2001 FY | 125.71 Million USD | 22.94% |
| 2000 Q3 | 96.33 Million USD | 1.93% |
| 2000 FY | 102.25 Million USD | 17.13% |
| 2000 Q2 | 94.5 Million USD | 3.51% |
| 2000 Q1 | 91.29 Million USD | 4.58% |
| 2000 Q4 | 102.25 Million USD | 6.15% |
| 1999 Q1 | 78.9 Million USD | 1.54% |
| 1999 Q4 | 87.3 Million USD | 1.75% |
| 1999 FY | 87.3 Million USD | 12.36% |
| 1999 Q3 | 85.8 Million USD | 4.25% |
| 1999 Q2 | 82.3 Million USD | 4.31% |
| 1998 FY | 77.7 Million USD | 37.52% |
| 1998 Q4 | 77.7 Million USD | 5.14% |
| 1998 Q3 | 73.9 Million USD | 2.78% |
| 1998 Q2 | 71.9 Million USD | 26.81% |
| 1998 Q1 | 56.7 Million USD | 0.35% |
| 1997 Q3 | 34.1 Million USD | 1.79% |
| 1997 FY | 56.5 Million USD | 183.92% |
| 1997 Q1 | 19.8 Million USD | -0.5% |
| 1997 Q4 | 56.5 Million USD | 65.69% |
| 1997 Q2 | 33.5 Million USD | 69.19% |
| 1996 FY | 19.9 Million USD | 323.4% |
| 1996 Q4 | 19.9 Million USD | 298.0% |
| 1996 Q1 | 5.3 Million USD | 12.77% |
| 1996 Q2 | 4.9 Million USD | -7.55% |
| 1996 Q3 | 5 Million USD | 2.04% |
| 1995 Q3 | 8 Million USD | -4.76% |
| 1995 Q1 | 8.9 Million USD | -4.3% |
| 1995 Q4 | 4.7 Million USD | -41.25% |
| 1995 FY | 4.7 Million USD | -49.46% |
| 1995 Q2 | 8.4 Million USD | -5.62% |
| 1994 FY | 9.3 Million USD | 5.68% |
| 1994 Q1 | 8.4 Million USD | -4.55% |
| 1994 Q3 | 9.7 Million USD | 21.25% |
| 1994 Q4 | 9.3 Million USD | -4.12% |
| 1994 Q2 | 8 Million USD | -4.76% |
| 1993 FY | 8.8 Million USD | 31.34% |
| 1993 Q1 | 6.6 Million USD | -1.49% |
| 1993 Q2 | 7.1 Million USD | 7.58% |
| 1993 Q3 | 8.2 Million USD | 15.49% |
| 1993 Q4 | 8.8 Million USD | 7.32% |
| 1992 FY | 6.7 Million USD | 34.0% |
| 1992 Q4 | 6.7 Million USD | -1.47% |
| 1992 Q1 | 5.6 Million USD | 12.0% |
| 1992 Q2 | 6.7 Million USD | 19.64% |
| 1992 Q3 | 6.8 Million USD | 1.49% |
| 1991 Q1 | 1 Million USD | 11.11% |
| 1991 Q4 | 5 Million USD | 61.29% |
| 1991 FY | 5 Million USD | 455.56% |
| 1991 Q3 | 3.1 Million USD | 6.9% |
| 1991 Q2 | 2.9 Million USD | 190.0% |
| 1990 Q4 | 900 Thousand USD | 0.0% |
| 1990 FY | 900 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -5645.839% |
| Dynavax Technologies Corporation | 252.41 Million USD | -454.785% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -4118.508% |
| Perrigo Company plc | 3.63 Billion USD | 61.452% |
| Illumina, Inc. | 1.48 Billion USD | 5.952% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 95.527% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -139937.6% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 82.591% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 89.19% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -705.958% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 48.19% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -5849.174% |
| Waters Corporation | 2.3 Billion USD | 39.26% |
| Biogen Inc. | 7.18 Billion USD | 80.518% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -4078.356% |
| Evolus, Inc. | 120.35 Million USD | -1063.499% |
| Adicet Bio, Inc. | 17.7 Million USD | -7810.388% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -3676.736% |
| bluebird bio, Inc. | 224.41 Million USD | -524.001% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -179.212% |
| FibroGen, Inc. | 89.69 Million USD | -1461.229% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 48.798% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -43139.752% |
| Homology Medicines, Inc. | 43.17 Million USD | -3143.413% |
| Geron Corporation | 35.05 Million USD | -3895.253% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 40.232% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -261.054% |
| Myriad Genetics, Inc. | 130.9 Million USD | -969.806% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -149512.821% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -1347.462% |
| Zoetis Inc. | 6.56 Billion USD | 78.666% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -31712.267% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 29.115% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -136.113% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -93.235% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -3995.864% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -2964.75% |
| Verastem, Inc. | 40.08 Million USD | -3393.429% |
| Nektar Therapeutics | 112.62 Million USD | -1143.397% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -686.419% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -45455.498% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -23.652% |
| OPKO Health, Inc. | 222.03 Million USD | -530.703% |
| Exelixis, Inc. | 189.94 Million USD | -637.257% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -442.151% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | -976.674% |
| Imunon, Inc. | 1.13 Million USD | -122816.23% |
| Blueprint Medicines Corporation | 610.96 Million USD | -129.208% |
| Insmed Incorporated | 1.19 Billion USD | -17.348% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 6.595% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -2357.317% |
| TG Therapeutics, Inc. | 100.11 Million USD | -1298.726% |
| Incyte Corporation | 29.16 Million USD | -4702.057% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -213.634% |